Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0WCBFK
ADC Name
Cirmtuzumab vedotin
Synonyms
UC-961ADC3
   Click to Show/Hide
Organization
University of California; Oncternal Therapeutics, Inc.
Drug Status
Investigative
Indication
In total 6 Indication(s)
B-cell chronic lymphocytic leukemia
Clinical candidate
.
Breast cancer
Clinical candidate
.
Castration-resistant prostatic cancer
Clinical candidate
.
Mantle cell lymphoma
Clinical candidate
.
Marginal zone B-cell lymphoma
Clinical candidate
.
Ovarian cancer
Clinical candidate
.
Drug-to-Antibody Ratio
2.5
Structure
Antibody Name
Cirmtuzumab
  Antibody Info 
Antigen Name
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Linker Name
Lysine-linker
 Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
Vedotin